Clik here to view.
enGene initiates $20 million financing to advance lead product
Closely held enGene of Vancouver is working on a financing of up to $20 million with venture capital funds to conduct the first two phases of human clinical trials of its intestinal immunotherapy...
View ArticleClik here to view.
Pluristem pioneering intramuscular placenta-based cell therapies
After two unsuccessful bone marrow transplants, a seven-year girl from Romania, suffering from a type of bone marrow failure and facing certain death, appears to be on the road to recovery after...
View ArticleClik here to view.
Leading the fight to repair myelin in MS patients
Two curious twists of fate led Scott Johnson to establish the Myelin Repair Foundation in 2003: the first was being diagnosed with multiple sclerosis 36 years ago at age 20; the second was reading a...
View ArticleClik here to view.
Ladenburg starts TG Therapeutics at buy
Ladenburg Thalmann has initiated coverage of TG Therapeutics (OTCBB:TGTX) with a “buy” rating and $6 price target, saying the target price is generated entirely from forecasted sales of TG-1101. TG is...
View ArticleClik here to view.
Leerink starts Xencor at outperform
Leerink Swann has initiated coverage of Xencor (NASDAQ:XNCR) with an “outperform” rating and an $11 price target. The stock closed at $9.20 on Friday. Xencor has used its proprietary “XmAb” platform to...
View ArticleClik here to view.
Gamida Cell shifts focus to NiCord stem cell product
Closely held Gamida Cell has shifted its focus to its second-generation stem cell product, NiCord, for the treatment of hematological malignancies and non-malignant hematological diseases in the wake...
View ArticleClik here to view.
Alpha Cancer to test oncology game changer
Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug...
View ArticleClik here to view.
HCW starts Aldeyra Therapeutics at buy
H.C. Wainwright has launched coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with a “buy” rating and a price target of $13. The stock closed at $7.65 on Monday. Analyst Swayampakula Ramakanth writes...
View ArticleClik here to view.
Can-Fite CEO to chair cancer conference session
Dr. Pnina Fishman, CEO of Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) will chair the plenary session titled, “Drugs Targeting Adenosine Receptors,” at the 2016 Keystone Symposia J5 in Vancouver,...
View ArticleClik here to view.
RedHill readying Phase 3 trials in Crohn’s
With a PDUFA target date of Feb. 3, 2014 for its migraine drug, RHB-103, and NDA filing planned for the first quarter of 2014 for the anti-emetic drug, RHB-102, RedHill Biopharma (NASDAQ,:RDHL;...
View Article
